Skip Ribbon Commands
Skip to main content

Find a Doctor

Dr Daniel Huang

Photo of Dr Daniel Huang
Designations:
  • Consultant, Division of Gastroenterology and Hepatology, Medicine, National University Hospital
  • Consultant, Liver Transplantation, National University Centre for Organ Transplantation, National University Hospital
  • Assistant Professor, Department of Medicine, Yong Loo Lin School of Medicine, National University of Singapore
Qualifications:
MBBS (S'pore), MMED (Int Med)(S'pore), MRCP (UK)
Specialties:
Medicine
Sub-specialties:
Adult Liver Transplantation Programme, Gastroenterology & Hepatology
Special Interests:
 
​Hepatocellular carcinoma, Liver transplantation, Non-alcoholic fatty liver disease, Hepatitis B

Biosketch

Dr Daniel Huang graduated from the Yong Loo Lin School of Medicine, National University of Singapore, and did his postgraduate residency training in NUH. He completed his fellowship in Gastroenterology and Hepatology, and was certified by the Specialist Accreditation Board of Singapore.

Dr Huang has a keen interest in liver transplantation, and is a member of the liver transplant team at the National University Hospital, Singapore. He is also proficient in diagnostic and therapeutic endoscopy.

Dr Huang’s research interest is in hepatocellular carcinoma oncogenesis in the setting of NAFLD and hepatitis B, and performs translational and clinical research in these areas.

Area of Interest:

  • Hepatocellular carcinoma
  • Liver transplantation
  • Non-alcoholic fatty liver disease
  • Hepatitis B

Awards

Yong Loo Lin School of Medicine Junior Doctor Teaching Award

  • Best oral presentation (GiHep)
  • Best oral presentation (UMC Academic Day)
  • Best oral presentation (NCSP)

Journals & Publications

  1. Huang, Q.D. & Lim, SG. New Advances in Hepatitis B Vaccination for Adults. Curr Hepatology Rep (2018). Epub 2018 Oct 8.
  2. Muthiah MD, Huang DQ, Zhou L, Jumat NH, Choolani M, Chan JKY, et al. A murine model demonstrating reversal of structural and functional correlates of cirrhosis with progenitor cell transplantation. Sci Rep. 2019 Oct 28;9(1):1–12.
  3. Hepatitis B: Who to treat? A critical review of international guidelines. Huang DQ, Lim SG. Liver Int. 2020 Feb;40 Suppl 1:5-14. doi: 10.1111/liv.14365.
  4. Identifying Patients With Cirrhosis Who Might Avoid Screening Endoscopy Based on Serum Albumin and Bilirubin and Platelet Counts.
    Kew GS, Chen ZJ, Yip AW, Huang YWC, Tan LY, Dan YY, Gowans M, Huang DQ, Lee GH, Lee YM, Lim SG, Low HC, Muthiah MD, Tai BC, Tan PS. Clin Gastroenterol Hepatol. 2019 Nov 9:S1542-3565(19)31270-4.
  5. Nucleoside analog monotherapy for prophylaxis in Hepatitis B liver transplant patients is safe and efficacious. Muthiah MD, Tan EY, Chua SHM, Huang DQY, Bonney GK, Kow AWC, Lim SG, Dan YY, Tan PS, Lee GH, Lim BL. Hepatol Int. 2020 Jan;14(1):57-69.
  6. A Brilliant Blue Liver. Bong SH, Soon GS, Huang DQ.
    Clin Gastroenterol Hepatol. 2020 Mar 12:S1542-3565(20)30282-2. doi: 10.1016/j.cgh.2020.03.009. Online ahead of print.
  7. Global prevalence, incidence, and outcomes of non-obese or lean non-alcoholic fatty liver disease: a systematic review and meta-analysis.
    Ye Q, Zou B, Yeo YH, Li J, Huang DQ, Wu Y et al. Lancet Gastroenterol Hepatol. 2020 May 12:S2468-1253(20)30077-7.
  8. Li J, Huang DQ, Zou B, et al. Epidemiology of COVID-19: A Systematic Review and Meta-analysis of Clinical Characteristics, Risk factors and Outcomes [published online ahead of print, 2020 Aug 13]. J Med Virol. 2020;10.1002/jmv.26424. doi:10.1002/jmv.26424
  9. Toyoda H, Huang DQ, Le MH, Nguyen M. Liver Care and Surveillance: The Global Impact of the COVID‐19 Pandemic. Hepatol Commun. 2020 Aug 3 : 10.1002/hep4.1579.
  10. Huang DQ, Yeo YH, Tan E et al. ALT Levels for Asians with Metabolic Diseases: A Meta-analysis of 86 Studies with Individual Patient Data Validation. Hepatol Commun 2020 Sep 9;4(11):1624-1636. doi: 10.1002/hep4.1593.
  11. Huang, D.Q. and Lim, S.G. (2020), Life After s Loss: Impact of Hepatitis B s Antigen Loss on Future Patient Outcomes. Clinical Liver Disease, 16: 262-265.
  12. Chen VL, Yeh ML, Yang JD, Leong J, Huang DQ, Toyoda H, Chen YL, Guy J, Maeda M, Tsai PC, Huang CF, Yasuda S, Le AK, Dang H, Giama NH, Ali HA, Zhang N, Wang X, Jun DW, Tseng CH, Hsu YC, Huang JF, Dai CY, Chuang WL, Zhu Q, Dan YY, Schwartz M, Roberts LR, Yu ML, Nguyen MH. Effects of Cirrhosis and Diagnosis Scenario in Metabolic-Associated Fatty Liver Disease-Related Hepatocellular Carcinoma. Hepatol Commun. 2020 Sep 24;5(1):122-132. doi: 10.1002/hep4.1606. PMID: 33437906; PMCID: PMC7789832.
  13. Huang DQ, Muthiah MD, Zhou L, Jumat H, Tan WX, Lee GH, Lim SG, Kow A, Bonney G, Shridhar I, Lim YT, Wee A, Pang YH, Soon G, Chow P, Dan YY. Predicting HCC Response to Multikinase Inhibitors With In Vivo Cirrhotic Mouse Model for Personalized Therapy. Cell Mol Gastroenterol Hepatol. 2020 Dec 16:S2352-345X(20)30208-3. doi: 10.1016/j.jcmgh.2020.12.009. Epub ahead of print. PMID: 33340714.
  14. Tan DJH, Wong C, Ng CH, Poh CW, Jain SR, Huang DQ, Muthiah MD. A Meta-Analysis on the Rate of Hepatocellular Carcinoma Recurrence after Liver Transplant and Associations to Etiology, Alpha-Fetoprotein, Income and Ethnicity. J Clin Med. 2021 Jan 11;10(2):E238. doi: 10.3390/jcm10020238. PMID: 33440759.
  15. Lim SG, Phyo WW, Ling JZJ, Cloherty G, Butler EK, Kuhns MC, McNamara AL, Holzmayer V, Gersch J, Yang WL, Ngu JH, Chang J, Tan J, Ahmed T, Dan YY, Lee YM, Lee GH, Tan PS, Huang DQ, Khine HTW, Lee C, Tay A, Chan E. Comparative biomarkers for HBsAg loss with antiviral therapy shows dominant influence of quantitative HBsAg (qHBsAg). Aliment Pharmacol Ther. 2021 Jan;53(1):172-182. doi: 10.1111/apt.16149. Epub 2020 Nov 7. PMID: 33159496.
  16. Huang DQ, Li X, Le MH et al. Natural History and Hepatocellular Carcinoma Risk in Untreated Chronic Hepatitis B Patients with Indeterminate Phase. Clin Gastroenterol Hepatol. 2021 Jan 16:S1542-3565(21)00069-0. doi: 10.1016/j.cgh.2021.01.019. Epub ahead of print. PMID: 33465482.
  17. Huang DQ, El-Serag HB, Loomba R. Global epidemiology of NAFLD-related HCC: trends, predictions, risk factors and prevention. Nat Rev Gastroenterol Hepatol. 2020 Dec 21. doi: 10.1038/s41575-020-00381-6. Epub ahead of print. PMID: 33349658.
  18. Huang DQ, Nguyen MH. Treatment eligibility in hepatitis B: a call for better linkage to optimal care. Lancet Gastroenterol Hepatol. 2021, in press.

Professional Memberships

  • ​Gastroenterological Society of Singapore (GESS)
  • Member of the Royal College of Physicians (UK)